Table 2. Best objective response to sorafenib.
All patients (n=61) No. (%) | No HTN (n=35) No. (%) | HTN (n=26) No. (%) | p | |
---|---|---|---|---|
CR | 1 (2.0) | 0 | 1 (4.5) | |
PR | 3 (5.9) | 0 | 3 (13.6) | |
SD | 15 (29.4) | 5 (17.2) | 10 (45.5) | |
PD | 32 (62.7) | 24 (82.8) | 8 (36.4) | |
Missing/NE | 10 | 6 | 4 | |
DCR (CR+PR+SD) | 19 (37.3) | 5 (17.2) | 14 (63.4) | 0.001 |
HTN, hypertension; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; DCR, disease control rate